Grant Number:	1R01CA172143-01 Interpret this number
Primary Investigator:	Hassett, Michael
Organization:	Dana-Farber Cancer Inst
Project Title:	Cancer Recurrence: Detection in Administrative Data, Incidence, and Costs
Fiscal Year:	2013

DESCRIPTION (provided by applicant): While some cancer deaths are attributable to progression of the primary disease, many, if not the majority, are due to recurrent metastatic cancer that develops after successful definitive therapy for earlier stage disease. Most tumor registries, including SEER, do not capture recurrence. Therefore, remarkably little is known about the population-based incidence or patterns and outcomes of care for advanced recurrent cancer. A valid and reliable algorithm for identifying such recurrences in administrative data would enable a literal explosion of comparative effectiveness research on this common, costly, and lethal condition. In particular, an algorithm that could be used to identify recurrence in administrative data would make it possible to (1) conduct studies using disease-free survival as an outcome, and (2) would enable the identification of inception cohorts in whom to study patterns and outcomes of care for advanced recurrent disease. Through an existing multidisciplinary collaboration between Dana-Farber Cancer Institute and Cancer Research Network investigators, we have made considerable progress on the development of a recurrence algorithm, working in two unique data sets that contain complete claims linked to gold standard data on recurrence. To date, we have shown that published recurrence identification strategies have unacceptably low sensitivity and specificity in our recent, population-based data sets, and have developed a highly promising two-phase probabilistic model that first determines the probability of recurrence and then estimates the date on which it occurred. We now propose to build on this work, conducting further development and validation of the algorithm, and then applying it to generate policy-relevant data on the public health burden imposed by recurrent advanced cancer. Specifically, we will: (1) complete the development of a candidate algorithm for detecting recurrence after definitive therapy of non-metastatic lung, colorectal, breast, and prostate cancer by incorporating use of cross-validation estimates and rigorously assessing algorithm performance~ (2) employ novel methods to directly and indirectly validate the algorithm in several entirely new data sets~ and (3) apply the validated algorithm to estimate the proportion of all-cause mortality attributable to recurrence and the total annualized costs of care for patients with recurrent disease, compared to patients presenting with advanced disease at diagnosis. As more cancer patients survive and survive longer, the population at risk for recurrence increases. Our algorithm will enable a new generation of research on the effectiveness, quality, and outcomes of cancer care that takes into account this sentinel event in the cancer trajectory. In our applied studies, we will begin to capitalize on this opportunity by measuring the impact of this condition on the public health and the consumption of societal resources.




Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer.
Authors: Banegas M.P. , Hassett M.J. , Keast E.M. , Carroll N.M. , O'Keeffe-Rosetti M. , Fishman P.A. , Uno H. , Hornbrook M.C. , Ritzwoller D.P. .
Source: Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, 2022 01; 25(1), p. 69-76.
EPub date: 2021-09-20 00:00:00.0.
PMID: 35031101
Related Citations

Regarding the Utility of Unstructured Data and Natural Language Processing for Identification of Breast Cancer Recurrence.
Authors: Ritzwoller D.P. , Hassett M.J. , Uno H. .
Source: Jco Clinical Cancer Informatics, 2021 Sep; 5, p. 1024-1025.
PMID: 34637320
Related Citations

Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease.
Authors: Hassett M.J. , Banegas M. , Uno H. , Weng S. , Cronin A.M. , O'Keeffe Rosetti M. , Carroll N.M. , Hornbrook M.C. , Ritzwoller D.P. .
Source: Journal Of Oncology Practice, 2019 Jul; 15(7), p. e616-e627.
EPub date: 2019-05-20 00:00:00.0.
PMID: 31107629
Related Citations

Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision.
Authors: Carroll N.M. , Ritzwoller D.P. , Banegas M.P. , O'Keeffe-Rosetti M. , Cronin A.M. , Uno H. , Hornbrook M.C. , Hassett M.J. .
Source: Jco Clinical Cancer Informatics, 2019 Mar; 3, p. 1-9.
PMID: 30869998
Related Citations

Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis.
Authors: Ritzwoller D.P. , Fishman P.A. , Banegas M.P. , Carroll N.M. , O'Keeffe-Rosetti M. , Cronin A.M. , Uno H. , Hornbrook M.C. , Hassett M.J. .
Source: Health Services Research, 2018 Dec; 53(6), p. 5106-5128.
EPub date: 2018-07-24 00:00:00.0.
PMID: 30043542
Related Citations

Determining the Time of Cancer Recurrence Using Claims or Electronic Medical Record Data.
Authors: Uno H. , Ritzwoller D.P. , Cronin A.M. , Carroll N.M. , Hornbrook M.C. , Hassett M.J. .
Source: Jco Clinical Cancer Informatics, 2018 12; 2, p. 1-10.
PMID: 30652573
Related Citations

Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer.
Authors: Hassett M.J. , Uno H. , Cronin A.M. , Carroll N.M. , Hornbrook M.C. , Ritzwoller D.P. .
Source: Jnci Cancer Spectrum, 2018 Apr; 2(2), p. pky024.
EPub date: 2018-06-28 00:00:00.0.
PMID: 30003196
Related Citations

Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
Authors: Ritzwoller D.P. , Hassett M.J. , Uno H. , Cronin A.M. , Carroll N.M. , Hornbrook M.C. , Kushi L.C. .
Source: Journal Of The National Cancer Institute, 2018-03-01 00:00:00.0; 110(3), p. 273-281.
PMID: 29873757
Related Citations

Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management.
Authors: Hassett M.J. , Uno H. , Cronin A.M. , Carroll N.M. , Hornbrook M.C. , Ritzwoller D. .
Source: Medical Care, 2017 12; 55(12), p. e88-e98.
PMID: 29135771
Related Citations

Survival after recurrence of stage I-III breast, colorectal, or lung cancer.
Authors: Hassett M.J. , Uno H. , Cronin A.M. , Carroll N.M. , Hornbrook M.C. , Fishman P. , Ritzwoller D.P. .
Source: Cancer Epidemiology, 2017-07-12 00:00:00.0; 49, p. 186-194.
EPub date: 2017-07-12 00:00:00.0.
PMID: 28710943
Related Citations

Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.
Authors: Hassett M.J. , Ritzwoller D.P. , Taback N. , Carroll N. , Cronin A.M. , Ting G.V. , Schrag D. , Warren J.L. , Hornbrook M.C. , Weeks J.C. .
Source: Medical Care, 2014 Oct; 52(10), p. e65-73.
PMID: 23222531
Related Citations